Following a previously successful collaboration, AbCellera will use its full stack, AI-powered antibody discovery technology to discover and identify a large panel of antibodies against new targets designated by Kodiak.
“Kodiak was one of AbCellera’s very first partners, and we are proud to expand our collaboration to support their innovative team in the fight against retinal diseases that cause blindness,” said Carl Hansen, Ph.D., President and CEO of AbCellera. “We are committed to making state-of-the-art antibody discovery broadly available to partners, empowering them to bring new therapies to patients quickly.”
Kodiak develops products and platforms to prevent and treat the leading causes of blindness. Kodiak’s ABC Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak’s discovery engine.
Under the terms of the agreement, AbCellera will receive research and development payments and is eligible for downstream milestone payments, as well as royalties on net sales. Other financial terms were not disclosed.
“In our previous work with AbCellera, they delivered quality therapeutic antibody candidates with unique epitope and bioactivity behaviors that were advanced for clinical development. We have been impressed with the growth and power of their platform, both the biology-driven as well as the software-driven aspects. We are delighted to work with their experienced and dedicated team again,” said Victor Perlroth, M.D., CEO of Kodiak Sciences.
“The value AbCellera brings to us as a partner is not only their state-of-the-art technology but also their expertise in working with us to discover superior and diverse therapeutic antibody candidates for novel disease targets.”